Pneumococcal vaccination

Current Opinion in Infectious Diseases

Volumn 29, Issue 2, 2016, Pages 187-196

  Cillóniz, Catia ^a   Amaro, Rosanel ^a   Torres, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Pneumococcal disease; Pneumonia; Streptococcus pneumoniae; Vaccination

Indexed keywords

PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ADVISORY COMMITTEE; ANTIBIOTIC RESISTANCE; ASPLENIA; BACTERIAL VIRULENCE; HUMAN; IMMUNIZATION; IMMUNOCOMPROMIZED PATIENT; INFECTION RISK; MEDICAL PRACTICE; PATHOGENESIS; PNEUMOCOCCAL INFECTION; REVIEW; SEROTYPE; TREATMENT OUTCOME; VACCINATION; EUROPE; IMMUNOLOGY; PNEUMOCOCCAL INFECTIONS; UNITED STATES; UTILIZATION;

EUROPE; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; UNITED STATES; VACCINATION;

EID: 84960110485     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000246     Document Type: Review

References (79)

1. Jansen AG, Rodenburg GD, van der EA, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009;49:e23-e29.
2. World Health Organization (WHO). Pneumococcal vaccines. Wkly Epidemiol Rec 2012;87:129-144.
3. World Health Organization (WHO). Progress in introduction of pneumococcal conjugate vaccine worldwide 2000-2012. 2013;88:173-180.
4. Aliberti S, Mantero M, Mirsaeidi M, Blasi F. The role of vaccination in preventing pneumococcal disease in adults. Clin Microbiol Infect 2014;20(Suppl 5):52-58.
5. Torres A, Bonanni P, Hryniewicz W, et al. Pneumococcal vaccination: what have we learnt so far and what can we expect in the future? Eur J Clin Microbiol Infect Dis 2015;34:19-31. Important review about pneumococcal vaccination and its clinical implication.
6. Bogaert D, de GR, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004;4:144-154.
7. Ferreira DM, Jambo KC, Gordon SB. Experimental human pneumococcal carriage models for vaccine research. Trends Microbiol 2011;19:464-470.
8. Grivea IN, Priftis KN, Giotas A, et al. Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece. Vaccine 2014;32:6513-6520.
9. Zuccotti G, Mameli C, Daprai L, et al. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era. Vaccine 2014;32:527-534.
10. Krone CL, Wyllie AL, van BJ, et al. Carriage of Streptococcus pneumoniae in aged adults with influenza-like-illness. PLoS One 2015;10:e0119875.
11. Almeida ST, Nunes S, Santos Paulo AC, et al. Low prevalence of pneumococcal carriage and high serotype and genotype diversity among adults over 60 years of age living in Portugal. PLoS One 2014;9:e90974.
12. Ansaldi F, de FD, Canepa P, et al. Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and longlasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation. Hum Vaccin Immunother 2013;9:614-620.
13. Hamaluba M, Kandasamy R, Ndimah S, et al. A cross-sectional observational study of pneumococcal carriage in children, their parents, and older adults following the introduction of the 7-valent pneumococcal conjugate vaccine. Medicine (Baltimore) 2015;94:e335.
14. Davis SM, oria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 2013;32:133-145.
15. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008;6:288-301.
16. Lawrence SL, Feil SC, Morton CJ, et al. Crystal structure of Streptococcus pneumoniae pneumolysin provides key insights into early steps of pore formation. Sci Rep 2015;5:14352.
17. Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev 2015;28:871-899.
18. Ardanuy C, Tubau F, Pallares R, et al. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 2009;48:57-64.
19. Lujan M, Gallego M, Belmonte Y, et al. Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J 2010;36:1073-1079.
20. Rodriguez MA, Gonzalez AV, Gavin MA, et al. Invasive pneumococcal disease: association between serotype, clinical presentation and lethality. Vaccine 2011;29:5740-5746.
21. Mook-Kanamori BB, Geldhoff M, Van Der PT, van de BD. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev 2011;24:557-591.
22. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 2007;82:93-104.
23. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009;30:189-209.
24. Grabenstein JD, Musey LK. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine 2014;32:2399-2405. Important review about the association of pneumococcal serotypes and serious clinical outcomes in adults.
25. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 68 2013;1057-1065. Important review about risk factors of community-acquired pneumonia in adults from Europe.
26. Cilloniz C, Ewig S, Polverino E, et al. Microbial aetiology of communityacquired pneumonia and its relation to severity. Thorax 2011;66:340-346.
27. Cilloniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 2013;144:999-1007.
28. Benard A, Mercie P, Alioum A, et al. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort 2000-2007. PLoS One 2010;5:e8896.
29. Cilloniz C, Ewig S, Polverino E, et al. Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J 2012;40:931-938.
30. Arnold FW, Wiemken TL, Peyrani P, et al. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2013;107:1101-1111.
31. Woodhead M, Welch CA, Harrison DA, et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17, 869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006;10(Suppl 2):S1.
32. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65:17-24.
33. Cilloniz C, Torres A, Polverino E, et al. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome. Eur Respir J 2014;43:1698-1708.
34. Grau I, Ardanuy C, Calatayud L, etal. Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections. Int J Infect Dis 2014;25:59-64.
35. Chapman KE, Wilson D, Gorton R. Invasive pneumococcal disease and socioeconomic deprivation: a population study from the North East of England. J Public Health (Oxf) 2013;35:558-569.
36. Almirall J, Serra-Prat M, Bolibar I, et al. Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based casecontrol study. BMJ Open 2014;4:e005133.
37. Bhatty M, Pruett SB, Swiatlo E, Nanduri B. Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses. Alcohol 2011;45:523-539.
38. Bello S, Menendez R, Torres A, et al. Tobacco smoking increases the risk for death from pneumococcal pneumonia. Chest 2014;146:1029-1037.
39. Feldman C, Anderson R. Recent advances in our understanding of Streptococcus pneumoniae infection. F1000Prime Rep 2014;6:82.
40. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 2014;20(Suppl 5):45-51.
41. Ludwig E, Bonanni P, Rohde G, et al. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012;21:57-65.
42. Mongardon N, Max A, Bougle A, et al. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care 2012;16:R155.
43. ThomasK, Mukkai KL, Veeraraghavan B, et al. Invasive pneumococcal disease associated with high case fatality in India. J Clin Epidemiol 2013;66:36-43.
44. Song JY, Choi JY, Lee JS, et al. Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study. BMC Infect Dis 2013;13:202.
45. Vila-Corcoles A, Ochoa-Gondar O. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging 2013;30:263-276.
46. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59:1102-1106.
47. Gutierrez Rodriguez MA, Ordobas Gavin MA, Garcia-Comas L, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid Spain, 2008-2011. Euro Surveill 2014;19:20922. A population-based cohort study involving 27 204 individuals of 60 years or older, assessed clinical effectiveness of PPV23 in preventing CAP among the general population aged greater than 60 years.
48. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against communityacquired pneumonia in the general population aged >60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014;58:909-917. Observational study that found that PPV23 vaccine protects elderly patients from hospitalization because of pneumococcal CAP, but female sex drives the effectiveness.
49. Johnstone J, Eurich DT, Minhas JK, etal. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high riskfor pneumonia. Clin Infect Dis 2010;51:15-22.
50. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013;1:CD000422.
51. Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012;30:6802-6808.
52. Leventer-Roberts M, Feldman BS, Brufman I, etal. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospitaltreated pneumonia among people aged >65 years: a retrospective casecontrol study. Clin Infect Dis 2015;60:1472-1480.
53. Wiemken TL, Carrico RM, Klein SL, et al. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine 2014;32:2198-2203.
54. Paradiso PR. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis 2011;52:1241-1247.
55. BlackS, Shinefield H, Fireman B, etal. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-195.
56. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368:1495-1502.
57. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349:1341-1348.
58. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010;362:812-822.
59. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010;28:4249-4259.
60. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010;14:e197-e209.
61. Moore MR, Whitney CG. Use of pneumococcal disease epidemiology to set policy and prevent disease during 20 years of the emerging infections program. Emerg Infect Dis 2015;21:1551-1556.
62. Palmu AA, Jokinen J, Nieminen H, et al. Effectiveness of the 10-valent pneumococcal conjugate vaccine against tympanostomy tube placements in a cluster-randomized trial. Pediatr Infect Dis J 2015;34:1230-1235.
63. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816-819.
64. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63:822-825.
65. Bonten MJ, HuijtsSM, Bolkenbaas M, etal. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1114-1125. A randomized double-blind, placebo-controlled trial (CAPITA) conducted in the Netherlands involving 84 496 adults aged greater than 65 years. Results demonstrated 45.5% efficacy of PCV13 gains all vaccine type pneumococcal CAP, 45% efficacy against vaccine-type nonbacteremic pneumococcal CAP, and 75% efficacy against vaccine type IPD among adults aged greater than 65 years.
66. Kim DK, Bridges CB, Harriman KH. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older-United States. MMWR Morb Mortal Wkly Rep 2015;64:91-92.
67. Jackson LA, Gurtman A, van CM, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013;31:3577-3584.
68. Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013;31:3585-3593.
69. Jackson LA, Gurtman A, van CM, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on antipneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013;31:3594-3602.
70. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine 2014;32:2364-2374.
71. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to nonpneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196:1346-1354.
72. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41.
73. Moore CE, Paul J, Foster D, et al. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis 2014;210:1001-1011.
74. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, populationbased surveillance. Lancet Infect Dis 2015;15:301-309.
75. Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015;15:535-543.
76. van der LM, Perniciaro S, Imohl M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis 2015;15:207.
77. Domenech M, Damian D, Ardanuy C, et al. Emerging, non-PCV13 serotypes 11A and 35B of Streptococcus pneumoniae show high potential for biofilm formation in vitro. PLoS One 2015;10:e0125636.
78. Camilli R, Daprai L, Cavrini F, et al. Pneumococcal carriage in young children one year after introduction of the 13-valent conjugate vaccine in Italy. PLoS One 2013;8:e76309.
79. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013;32:203-207.